Clinical Features and Prognosis Analysis of Hormone Receptor-Positive, HER2-Negative Breast Cancer with Differential Expression Levels of Estrogen and Progesterone Receptors: A 10-Year Retrospective Study
Table 3
Multivariate analysis of factors associated with DFS and OS.
Characteristics
DFS
OS
HR (95% CI)
value
HR (95% CI)
value
Age (y; ≥50 vs.<50)
0.44 (0.148–1.307)
0.139
0.537 (0.136–2.118)
0.375
Menstrual status (post-vs. Pre-)
3.015 (0.971–9.359)
0.056
8.466 (1.571–45.618)
0.013
Histology type (NST vs. NI&IST)
1.196 (0.287–4.978)
0.805
0.841 (0.189–3.741)
0.82
Ki-67 (≥14% vs. <14%)
1.013 (0.457–2.246)
0.974
0.695 (0.218–2.216)
0.538
Tumor size (cm)
0.039
0.015
T2 vs. T1
0.904 (0.39–2.096)
0.814
0.385 (0.119–1.252)
0.113
T3 vs. T1
5.862 (1.392–24.68)
0.016
4.421 (0.823–23.758)
0.083
T4 vs. T1
2.455 (0.367–16.42)
0.354
5.719 (0.45–72.68)
0.179
ALN status
≤0.001
0.008
1–3 vs. 0
3.278 (1.12–9.591)
0.003
5.053 (1.313–19.444)
0.018
≥4 vs. 0
10.914 (4.073–29.24)
≤0.001
7.594 (1.897–25.949)
0.004
Breast surgery
0.377
0.104
SM vs. BCS
0.405 (0.035–4.726)
0.471
0.493 (0.041–5.99)
0.579
MRM vs. BCS
0.333 (0.091–1.224)
0.098
0.184 (0.043–0.785)
0.022
ERM vs. BCS
0.526 (0.098–2.83)
0.454
0.415 (0.06–2.879)
0.373
Group
0.061
0.052
ER > 10%&1% ≤ PR ≤ 20% vs. ER > 10% &PR>20%
2.87 (1.196–6.887)
0.018
3.813 (1.204–12.077)
0.023
1% ≤ ER ≤ 10%&1% ≤ PR ≤ 20% vs. ER > 10% &PR > 20%
1.963 (0.492–7.83)
0.339
3.738 (0.738–18.936)
0.111
1% ≤ ER ≤ 10%&1% ≤ PR ≤ 20% vs. ER > 10%&1% ≤ PR ≤ 20%
